In the past 30 years, huge number of anti-AR drugs have been developed and approved for different stages of prostate cancer, such as flutamide, bicalutamide, nilumet, and enzalutamide (Bassetto et al., 2016). This evidence concerns the gene AR and prostate carcinoma.